Cingulate Inc. (CING)
CINGNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$4.21
-0.2800 (-6.24%) today
Regular session, Nov 13, 11:35 AM ET
- Market cap
- $61.22m
- P/E
- –
- EPS, last 4 quarters
- $-3.59
- Dividend yield
- –
- Day range
- $4.18 to $4.60
- 52-week range
- $3.16 to $11.89
- Average volume
- –
- Previous close
- $4.49
Analysts
3 coveringBuy3 buy, 0 hold, 0 sell
Targets a year out average $20.33, +382.9% from here
Earnings
next estimate $-0.4800Next report
Sep 2025
-68.8%
Dec 2025
-50.0%
Mar 2026
-79.3%
Jun 2026
+28.6%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$6.00m | -$5.59m | -$7.92m | -$5.42m |
| Net income | -$7.34m | -$6.27m | -$9.31m | -$5.87m |
News
8 latest- Weekly Buzz: PHG, KMDA Win FDA Nod; FULC Halts Pociredir; RMD Closes Noctrix Deal; NVS Paces In IgAN RTTNews · Jun 5, 2026
- Top Biotech Gainers: ABVX, CING, DRTS, MMED... RTTNews · Jun 3, 2026
- Top Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL RTTNews · Jun 2, 2026
- FDA Issues CRL To Cingulate Requesting CMC Information On ADHD Drug CTx-1301; Stock Up RTTNews · Jun 2, 2026
- Cingulate Receives FDA Complete Response Letter For ADHD Drug CTx-1301 RTTNews · Jun 2, 2026
- Biotech Stocks Facing FDA Decision In May 2026 RTTNews · Apr 28, 2026
- Biotech Sector Sees Broad After-Hours Gains Amid Quiet News Flow RTTNews · Jan 22, 2026
- Ascendiant Capital Maintains Cingulate (CING) Buy RecommendationFintel · Dec 8, 2025
The company
Cingulate Inc. (NASDAQ: CING) is a biopharmaceutical company utilizing its proprietary PTR drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of ADHD, Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders. Cingulate is headquartered in Kansas City. For more information, visit Cingulate.com.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- cingulate.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.